Dr. Mark Sausen has driven the planning, development and execution of projects in genetics and genomics for life sciences companies and academic research centers over the past 15 years. Previously, as Vice President, Research and Development at PGDx, he led the development of their NGS-based in vitro diagnostic platforms, achieving proof of concept for plasma-based detection capabilities which contributed to a US Food and Drug Administration (FDA) breakthrough device designation. Dr. Sausen was most recently Scientific Director, Clinical Genetics and Genomics, at Bristol Myers Squibb. In this role, he co-led platform development and partnered strategies for liquid biopsy clinical development opportunities and guided exploratory genomics applications with respect to solid tumor disease biology, pharmacodynamics and patient segmentation.
Dr. Sausen has also contributed to research at the Ludwig Center for Cancer Genetics and Therapeutics, the Helen F. Graham Cancer Center and the Human Performance Laboratory. Dr. Sausen holds a PhD in cellular and molecular medicine from Johns Hopkins School of Medicine and has received numerous awards and research grants for his work in genomics and diagnostics.